Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Leveraging computerized maintenance management systems software can enhance efficiency, improve quality control, ensure ...

Choosing dividend stocks is not only about looking at the yield but also ensuring that the company pays regular dividends, ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new discoveries to American companies. The big picture: China has become a linchpin in ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...

Real-estate company Metro Loft Developers and David Werner Real Estate Investments, a commercial real-estate investment ...